Lung


This 90-minute presentation will review the state-of-the-art treatment approaches for lung cancer. The presentation will include best-practices for lung cancer: (1) role of lung cancer screening, (2) staging, (3) appropriate clinical work-up, (4) incorporating multi-modality imaging, (5) advanced radiation treatment planning (IMRT, SABR, hypofractionated), (6) using modern image-guidance and advanced delivery techniques (non-coplanar therapy, proton therapy, MR-guided radiotherapy). The course will also review the relevant evidence-based literature on the incorporation of radiotherapy for stages I-IV for Non-small-cell lung cancer (NSCLC), oligometastatic NSCLC, as well as limited and extensive stage SCLC.

Target Audience

The activity is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, nurses and all other health professionals involved in the field of radiation oncology.

 

Learning Objectives

Upon completion of this live activity, attendees should be able to do the following:

1.    Identify the role of lung cancer screening, best-practices using low-dose CT for lung cancer screening, who are the optimal candidates to offer lung cancer screening, and the best treatment options for screen-detected early stage lung cancer
2.    Offer best-practice multimodality therapies for limited and extensive stage small cell lung cancer including incorporating prophylactic cranial irradiation and consolidative thoracic radiation therapy when appropriate.
3.    Determine who are inoperable early stage NSCLC lung cancer patients, and use best-practices to deliver the highest quality SABR for these patients
4.    Offer optimal chemoradiotherapy to patients with unresectable stage III NSCLC in conjunction with consolidative durvalumab.
5.    Identify who are the optimal candidates with oligometastatic or oligoprogressive NSCLC that will most likely derive a clinical benefit with aggressive local consolidative therapies (e.g. surgery or SABR).

 

Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.50 Certificate of Attendance
    This activity was designated for 1.50 AMA PRA Category 1 Credit™.
Course opens: 
04/07/2020
Course expires: 
04/06/2023
Cost:
$0.00
Part of: 
2020 ASTRO Annual Refresher Course - onDemand
Rating: 
0


Percy Lee, MD, is employed by  MD Anderson Cancer Center and receives compensation/remuneration/funding AstraZeneca, Inc., Varian Inc., and  Viewray.
 

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.

 

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.50 Certificate of Attendance
    This activity was designated for 1.50 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.